Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELENE 2: Lenbelintide in Type 2 Diabetes and Obesity
NCT07784270Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Countries
- 16
01
Overview
A Phase 3 trial of lenbelintide in obesity, type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Aug 2026; status: recruiting.
02
Drugs
lenbelintide
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07784270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07784270.